Clinical Trial Goal
To find out if the combination of dexamethasone, leflunomide and pomalidomide is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Have been treated with bortezomib, carfilzomib, ixazomib or another proteasome inhibitor. Your doctor can tell you this
- Have been treated with lenalidomide, pomalidomide, thalidomide or another immunomodulatory drug. Your doctor can tell you this
- Do not have myeloma that is refractory to treatment with pomalidomide. Your doctor can tell you this
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Leflunomide is a drug that slows down the immune system and reduces inflammation.
Pomalidomide is a drug that blocks the growth of cancer cells.
You’ll get:
Pomalidomide is a drug that blocks the growth of cancer cells.
You’ll get:
- Dexamethasone – A pill that you take by mouth 1 time each week
- Leflunomide – A pill that you take by mouth 1 time each day
- Pomalidomide – A pill that you take by mouth 1 time each day for the first three weeks of each month
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have scans and biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved the combination of dexamethasone and pomalidomide to treat multiple myeloma that has relapsed or is refractory. The FDA has approved leflunomide to treat an inflammatory condition called rheumatoid arthritis. Using the combination of dexamethasone, leflunomide and pomalidomide to treat multiple myeloma that has relapsed or is refractory is new and unproven.
Locations
City of Hope Medical CenterRECRUITING
Duarte, California
Michael A. Rosenzweig, 626-256-4973, mrosenzweig@coh.org
Sponsors
collaborator: National Cancer Institute (NCI), lead: City of Hope Medical Center
